EXPERT HIGHLIGHTS: BLADDER CANCER
SIU Academy®. Faculty / Presenter(s) . 11/07/20; 312685
Topic: Treatment
Faculty / Presenter(s)
About this activity
Over the past 10 years, advancements in genomics and sequencing technologies have paved the way to a more in-depth understanding of the pathogenesis of bladder cancer, leading to the discovery of new targets. The development of several novel therapies such as checkpoint inhibitors, and other targeted therapies have allowed for a more optimized treatment approach. A number of new drugs in 2019 and early 2020 were approved by the U.S. Food and Drug Administration (FDA) for all stages of bladder cancer.
Faculty:
Moderator
Wes Kassouf, MD, CM, FRCSC
Stephen Jarislowsky Chair in Urology
Professor and Vice Chair, Dept of Surgery
McGill University
Canada
Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Medical Director – Clinical Trials Office
Perlmutter Cancer Center
United States
Kilian M Gust, MD
Department of Urology
Medical University of Vienna
Austria
Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Canada
This educational activity is supported by SIU Corporate Sponsor Bristol Myers Squibb.
Faculty:
Moderator
Wes Kassouf, MD, CM, FRCSC
Stephen Jarislowsky Chair in Urology
Professor and Vice Chair, Dept of Surgery
McGill University
Canada
Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Medical Director – Clinical Trials Office
Perlmutter Cancer Center
United States
Kilian M Gust, MD
Department of Urology
Medical University of Vienna
Austria
Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Canada
This educational activity is supported by SIU Corporate Sponsor Bristol Myers Squibb.
{{ help_message }}